Tazarotene

Treats plaque psoriasis of up to 20% body surface area involvement. Sold as Tazorac, Avage, Fabior, Arazlo. Every FDA application for this active ingredient: 4 branded and 10 generic.

As of Nov 15, 2026, FDA lists 14 applications for Tazarotene (sold as Tazorac, Avage, Fabior and others), first approved Jun 13, 1997, with 2 new uses approved and 0 published complete response letters.

First approved: Jun 13, 1997
Applications: 14
New uses approved: 2
Complete response letters: 0
Medicare spending, 2025: $4.2M

Medicare Spending

CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name


Tazarotene	Part D	$3.2M	+35%	7,340
Tazorac	Part D	$607K	-58%	176
Arazlo	Part D	$321K	-9%	342
Fabior	Part D	$44K	+30%	12

What Pharmacies Pay

Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change

TAZAROTENE 0.05% CREAM: $7.64 per GMGeneric · -15% in a year
TAZAROTENE 0.05% GEL: $5.92 per GMGeneric · -13% in a year
TAZAROTENE 0.1% CREAM: $1.91 per GMGeneric · -15% in a year
TAZAROTENE 0.1% GEL: $6.03 per GMGeneric · -24% in a year
FABIOR 0.1% FOAM: $12.32 per GMBrand · -1% in a year

Orphan Designations (FDA)

One designation, 0 approved for the designated use; see all orphan designations

treatment of idiopathic pulmonary fibrosisGRI Bio Operations, Inc. · designated Jun 17, 2026

Applications

NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history


Jun 13, 1997	TazoracNDA 20600 · New molecular entity	Chartwell Rx	7	Marketed
Sep 29, 2000	Tazorac, AvageNDA 21184 · New dosage form	Chartwell Rx	5	Marketed
May 11, 2012	FabiorNDA 202428 · New dosage form	Mayne Pharma	0	Marketed
Apr 3, 2017	TazaroteneANDA 208258	Sun Pharma Canada	0	Marketed
Dec 22, 2017	TazaroteneANDA 208662	Cosette Pharms Nc	1	Marketed
Jan 28, 2019	TazaroteneANDA 211175	Fougera Pharms Inc	0	Discontinued
Dec 18, 2019	ArazloNDA 211882 · New formulation or manufacturer	Bausch	0	Marketed
Sep 13, 2022	TazaroteneANDA 214136	Cosette Pharms Nc	0	Marketed
Sep 13, 2022	TazaroteneANDA 215433	Cosette Pharms Nc	0	Marketed
Mar 20, 2023	TazaroteneANDA 213644	Solaris Pharma Corp	0	Marketed
Apr 25, 2023	TazaroteneANDA 213079	Padagis Israel	0	Marketed
Jul 15, 2024	TazaroteneANDA 217075	Padagis Israel	0	Marketed
Jul 29, 2025	TazaroteneANDA 215393	Padagis Israel	0	Discontinued
Nov 24, 2025	TazaroteneANDA 214560	Solaris Pharma Corp	0	Marketed

Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA